These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 29158574)

  • 1. Immunogenicity and loss of response to TNF inhibitors: implications for rheumatoid arthritis treatment.
    Kalden JR; Schulze-Koops H
    Nat Rev Rheumatol; 2017 Nov; 13(12):707-718. PubMed ID: 29158574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.
    Garcês S; Antunes M; Benito-Garcia E; da Silva JC; Aarden L; Demengeot J
    Ann Rheum Dis; 2014 Jun; 73(6):1138-43. PubMed ID: 23666932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events.
    Prado MS; Bendtzen K; Andrade LEC
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):985-995. PubMed ID: 28772079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept.
    Jamnitski A; Bartelds GM; Nurmohamed MT; van Schouwenburg PA; van Schaardenburg D; Stapel SO; Dijkmans BA; Aarden L; Wolbink GJ
    Ann Rheum Dis; 2011 Feb; 70(2):284-8. PubMed ID: 21068090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.
    Hyrich KL; Lunt M; Watson KD; Symmons DP; Silman AJ;
    Arthritis Rheum; 2007 Jan; 56(1):13-20. PubMed ID: 17195186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?
    Mehta P; Manson JJ
    Front Immunol; 2020; 11():589. PubMed ID: 32318070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of anti-TNF biologic agents in the treatment of rheumatoid arthritis.
    Mok CC; Tsai WC; Chen DY; Wei JC
    Expert Opin Biol Ther; 2016; 16(2):201-11. PubMed ID: 26560845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-alpha neutralization in cytokine-driven diseases: a mathematical model to account for therapeutic success in rheumatoid arthritis but therapeutic failure in systemic inflammatory response syndrome.
    Jit M; Henderson B; Stevens M; Seymour RM
    Rheumatology (Oxford); 2005 Mar; 44(3):323-31. PubMed ID: 15585509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Golimumab trough levels, antidrug antibodies and clinical response in patients with rheumatoid arthritis treated in daily clinical practice.
    Kneepkens EL; Plasencia C; Krieckaert CL; Pascual-Salcedo D; van der Kleij D; Nurmohamed MT; López-Casla MT; Wieringa R; Rispens T; Wolbink G
    Ann Rheum Dis; 2014 Dec; 73(12):2217-9. PubMed ID: 25261580
    [No Abstract]   [Full Text] [Related]  

  • 11. [How I treat...rheumatoid arthritis. The arrival of a new therapeutic era: anti-tumor necrosis factor alpha antibodies].
    Kaiser MJ; Malaise MG
    Rev Med Liege; 2002 Aug; 57(8):486-92. PubMed ID: 12405019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis].
    Mugnier B; Bouvenot G
    Rev Med Interne; 2000 Oct; 21(10):854-62. PubMed ID: 11075394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies.
    Bandrés Ciga S; Salvatierra J; López-Sidro M; García-Sánchez A; Durán R; Vives F; Raya-Álvarez E
    J Clin Rheumatol; 2015 Apr; 21(3):115-9. PubMed ID: 25807089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
    Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
    Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
    Bartelds GM; Krieckaert CL; Nurmohamed MT; van Schouwenburg PA; Lems WF; Twisk JW; Dijkmans BA; Aarden L; Wolbink GJ
    JAMA; 2011 Apr; 305(14):1460-8. PubMed ID: 21486979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging biologic drugs for the treatment of rheumatoid arthritis.
    Puppo F; Murdaca G; Ghio M; Indiveri F
    Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rheumatoid Arthritis - Anti-TNF.
    Chaabo K; Kirkham B
    Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of antidrug antibodies on the sustainable efficacy of biologic therapies in rheumatoid arthritis: practical consequences.
    Keiserman M; Codreanu C; Handa R; Xibillé-Friedmann D; Mysler E; Briceño F; Akar S
    Expert Rev Clin Immunol; 2014 Aug; 10(8):1049-57. PubMed ID: 24961616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
    Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
    Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.